Investors who purchased or acquired Hims & Hers Health, Inc. securities between Aug. 4, 2025, and July 29, 2026, inclusive, have until Nov. 2, 2026, to seek appointment as lead plaintiff in a proposed securities class action. The case, Velanki v. Hims & Hers Health, Inc., No. 26-cv-09313 (N.D. Cal.), alleges that Hims & Hers and certain top executives violated the Securities Exchange Act of 1934 by misleading investors about consumer health-information sharing, prescription billing, cancellation practices, regulatory scrutiny, potential fees and penalties, and the company’s business prospects. The allegations center on a Federal Trade Commission lawsuit announced July 29, 2026, concerning the sharing of sensitive health information with third-party advertising platforms and billing and cancellation practices. Hims & Hers shares declined nearly 15% following the news, according to the complaint. Investors may seek lead-plaintiff status under the Private Securities Litigation Reform Act of 1995, but they do not need to act immediately to remain absent class members or participate in any potential recovery.